Andrea Russo1, Francesco Morescalchi, Sara Vezzoli, Marzia Bernini, Raffaele Turano, Ciro Costagliola, Francesco De Ferrari, Francesco Semeraro. 1. *Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy; †Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Section of Legal Medicine, University of Brescia, Brescia, Italy; and ‡Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.
Abstract
PURPOSE: To assess vitreous concentrations of nonsteroidal anti-inflammatory drugs (NSAIDs) and prostaglandin E2 (PGE2) in patients treated with NSAIDs before vitrectomy for macular pucker. METHODS: A prospective, investigator-masked, randomized study was performed in 64 patients scheduled to undergo vitrectomy. The patients were randomized 1:1:1:1 to receive indomethacin 0.5%, bromfenac 0.09%, nepafenac 0.1%, or placebo three times a day. NSAIDs and PGE2 levels were evaluated in vitreous samples collected at the beginning of surgery. RESULTS:Mean (SD) vitreous concentrations of the study drugs were 503.13 (241.1) pg/mL for indomethacin, 302.5 (91.03) pg/mL for bromfenac, and 284.38 (128.2) pg/mL for nepafenac. Mean (SD) vitreous PGE2 levels were 247.9 (140.9) pg/mL for indomethacin, 322.12 (228.1) pg/mL for bromfenac, 448.8 (261.1) pg/mL for nepafenac, and 1,133 (323.9) pg/mL for placebo. All three NSAIDs reduced vitreous PGE2 levels to a statistically significant extent, without a significant difference among them. CONCLUSION: All assessed NSAIDs penetrated the vitreous and lowered basal PGE2 levels. A greater penetration was associated with pseudophakic eyes. The important inhibition of prostaglandins in the retina may have a clinical effect on the management of inflammatory retina diseases.
RCT Entities:
PURPOSE: To assess vitreous concentrations of nonsteroidal anti-inflammatory drugs (NSAIDs) and prostaglandin E2 (PGE2) in patients treated with NSAIDs before vitrectomy for macular pucker. METHODS: A prospective, investigator-masked, randomized study was performed in 64 patients scheduled to undergo vitrectomy. The patients were randomized 1:1:1:1 to receive indomethacin 0.5%, bromfenac 0.09%, nepafenac 0.1%, or placebo three times a day. NSAIDs and PGE2 levels were evaluated in vitreous samples collected at the beginning of surgery. RESULTS: Mean (SD) vitreous concentrations of the study drugs were 503.13 (241.1) pg/mL for indomethacin, 302.5 (91.03) pg/mL for bromfenac, and 284.38 (128.2) pg/mL for nepafenac. Mean (SD) vitreous PGE2 levels were 247.9 (140.9) pg/mL for indomethacin, 322.12 (228.1) pg/mL for bromfenac, 448.8 (261.1) pg/mL for nepafenac, and 1,133 (323.9) pg/mL for placebo. All three NSAIDs reduced vitreous PGE2 levels to a statistically significant extent, without a significant difference among them. CONCLUSION: All assessed NSAIDs penetrated the vitreous and lowered basal PGE2 levels. A greater penetration was associated with pseudophakic eyes. The important inhibition of prostaglandins in the retina may have a clinical effect on the management of inflammatory retina diseases.
Authors: Francesco Semeraro; Elena Gambicordi; Anna Cancarini; Francesco Morescalchi; Ciro Costagliola; Andrea Russo Journal: Br J Clin Pharmacol Date: 2019-02-28 Impact factor: 4.335
Authors: Andrea Russo; Nicolò Scaroni; Elena Gambicorti; Raffaele Turano; Francesco Morescalchi; Ciro Costagliola; Francesco Semeraro Journal: Clin Ophthalmol Date: 2018-03-27
Authors: Ricardo Raúl Robles-Rivera; José Alberto Castellanos-González; Cecilia Olvera-Montaño; Raúl Alonso Flores-Martin; Ana Karen López-Contreras; Diana Esperanza Arevalo-Simental; Ernesto Germán Cardona-Muñoz; Luis Miguel Roman-Pintos; Adolfo Daniel Rodríguez-Carrizalez Journal: Oxid Med Cell Longev Date: 2020-03-11 Impact factor: 6.543